These results suggest that FAK and PYK2 may serve as potential therapeutic targets in CLL, offering a novel strategy aimed at modulating the mechanical properties of cancer cells and their microenvironment [189]. Here, PTK2 is linked to B-cell chronic lymphocytic leukemia.